MLLT3
Basic information
Region (hg38): 9:20341669-20622499
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MLLT3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 22 | 22 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 22 | 4 | 1 |
Variants in MLLT3
This is a list of pathogenic ClinVar variants found in the MLLT3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
9-20346495-T-C | not specified | Uncertain significance (Mar 16, 2024) | ||
9-20354863-C-T | not specified | Uncertain significance (Jun 11, 2021) | ||
9-20360768-G-C | not specified | Uncertain significance (Jul 26, 2022) | ||
9-20360785-T-C | not specified | Uncertain significance (Dec 06, 2022) | ||
9-20360786-G-A | not specified | Uncertain significance (Nov 14, 2023) | ||
9-20363486-G-C | not specified | Uncertain significance (Dec 22, 2023) | ||
9-20363492-C-T | not specified | Uncertain significance (Sep 23, 2023) | ||
9-20363506-G-A | not specified | Uncertain significance (Feb 22, 2023) | ||
9-20363575-T-C | not specified | Uncertain significance (Apr 11, 2023) | ||
9-20363581-T-C | not specified | Uncertain significance (May 21, 2024) | ||
9-20363593-G-T | not specified | Uncertain significance (Apr 07, 2022) | ||
9-20363596-C-T | not specified | Uncertain significance (Jul 16, 2021) | ||
9-20413761-T-C | not specified | Uncertain significance (May 25, 2023) | ||
9-20413788-G-A | not specified | Uncertain significance (Oct 12, 2022) | ||
9-20413794-G-A | not specified | Uncertain significance (Aug 02, 2021) | ||
9-20413813-A-G | not specified | Uncertain significance (Oct 26, 2022) | ||
9-20413912-T-C | not specified | Uncertain significance (Jun 12, 2023) | ||
9-20413965-G-A | not specified | Uncertain significance (Aug 01, 2022) | ||
9-20413992-G-A | not specified | Uncertain significance (Apr 27, 2022) | ||
9-20414108-T-G | not specified | Uncertain significance (Sep 29, 2023) | ||
9-20414151-G-A | not specified | Uncertain significance (Feb 21, 2024) | ||
9-20414163-G-T | not specified | Uncertain significance (Aug 04, 2021) | ||
9-20414306-G-A | Likely benign (Nov 01, 2022) | |||
9-20414307-C-G | not specified | Uncertain significance (Jun 26, 2023) | ||
9-20414310-C-T | not specified | Uncertain significance (Feb 27, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MLLT3 | protein_coding | protein_coding | ENST00000380338 | 11 | 280880 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.000361 | 125641 | 0 | 2 | 125643 | 0.00000796 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.90 | 205 | 297 | 0.690 | 0.0000141 | 3851 |
Missense in Polyphen | 45 | 99.995 | 0.45002 | 1355 | ||
Synonymous | -2.57 | 140 | 106 | 1.32 | 0.00000540 | 974 |
Loss of Function | 4.42 | 0 | 22.7 | 0.00 | 0.00000104 | 320 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000914 | 0.00000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000328 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA (PubMed:20159561, PubMed:20471948, PubMed:25417107, PubMed:27105114, PubMed:27545619). Specifically recognizes and binds acylated histone H3, with a marked preference for histone H3 that is crotonylated (PubMed:25417107, PubMed:27105114, PubMed:27545619). Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors (PubMed:25417107, PubMed:27105114, PubMed:27545619). Recognizes and binds histone H3 crotonylated at 'Lys-9' (H3K9cr), and with slightly lower affinity histone H3 crotonylated at 'Lys-18' (H3K18cr) (PubMed:27105114). Also recognizes and binds histone H3 acetylated at 'Lys-9' (H3K9ac), but with lower affinity than crotonylated histone H3 (PubMed:25417107, PubMed:27105114). In the SEC complex, MLLT3 is required to recruit the complex to crotonylated histones (PubMed:27105114, PubMed:27545619). {ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948, ECO:0000269|PubMed:25417107, ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving MLLT3 is associated with acute leukemias. Translocation t(9;11)(p22;q23) with KMT2A/MLL1. The result is a rogue activator protein. {ECO:0000269|PubMed:10861294, ECO:0000269|PubMed:8506309}.; DISEASE: Note=A chromosomal aberration involving MLLT3 was observed in a patient with neuromotor development delay, cerebellar ataxia and epilepsy. Translocation t(4;9)(q35;p22). {ECO:0000269|PubMed:16001262}.;
- Pathway
- Transcriptional misregulation in cancer - Homo sapiens (human);Gene expression (Transcription);RNA Polymerase II Pre-transcription Events;Formation of RNA Pol II elongation complex ;RNA Polymerase II Transcription;RNA Polymerase II Transcription Elongation
(Consensus)
Recessive Scores
- pRec
- 0.203
Intolerance Scores
- loftool
- 0.0415
- rvis_EVS
- -0.36
- rvis_percentile_EVS
- 28.93
Haploinsufficiency Scores
- pHI
- 0.514
- hipred
- Y
- hipred_score
- 0.825
- ghis
- 0.621
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.903
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mllt3
- Phenotype
- hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; embryo phenotype; immune system phenotype; skeleton phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- regulation of transcription by RNA polymerase II;transcription by RNA polymerase II;transcription elongation from RNA polymerase II promoter;segment specification;anterior/posterior pattern specification;positive regulation of transcription, DNA-templated;negative regulation of canonical Wnt signaling pathway;positive regulation of Wnt signaling pathway, planar cell polarity pathway
- Cellular component
- nucleus;nucleoplasm;chromosome;transcription elongation factor complex;extracellular exosome
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;chromatin binding;protein binding;histone binding;lysine-acetylated histone binding;modification-dependent protein binding